Journal
EXPERT REVIEW OF VACCINES
Volume 9, Issue 10, Pages 1127-1133Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/ERV.10.117
Keywords
active immunization; aged; aging; human; immune system; immunization; immunosenescence; inactivated; influenza; influenza vaccine; vaccine; viral vaccine
Categories
Ask authors/readers for more resources
On 23 December 2009, the US FDA approved Fluzone (R) High Dose, a high-dose formulation of the trivalent inactivated influenza vaccine, for prevention of influenza in people 65 years of age and older. As it was approved via an accelerated process designed to allow expeditious availability of safe and effective products with promise to treat or prevent serious or life-threatening diseases, the manufacturer is required to conduct further studies to demonstrate effectiveness. Although these studies are underway, a recently completed randomized, controlled trial demonstrated that this vaccine, containing four-times more hemagglutinin than standard-dose inactivated influenza vaccines, can produce an enhanced immunologic response in subjects of 65 years of age and older, while maintaining a favorable safety profile. This article introduces the vaccine, presents currently available safety and immunogenicity data, discusses current recommendations for use, and proposes what we can expect in the coming years.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available